Welcome!

News Feed Item

NanoAntibiotics to Begin Trading on the OTC Markets

Company Developing New Arsenal to Fight Multi-Drug Resistant Bacteria

BOSTON, MA -- (Marketwired) -- 05/05/14 -- NanoAntibiotics Inc. (OTCQB: NNAB) (the "Company"), a development stage nano-biotechnology company focused on the discovery, development, and commercialization of new anti-infective drugs to meet the growing clinical need created by multi-drug resistant bacterial pathogens, is pleased to announce that it has been informed that trading of its stock is to begin on the OTC Markets.

"We are excited to be making our debut in the public marketplace and committed to providing our investors with access to information on the Company," says Rajah Menon, NanoAntibiotics President and Director. "We are constantly advancing towards our goal of creating the world's ultimate weapon against bacteria, the first drug that will solve the bacterial efflux issue. Progress is continuing in the development of our platform that will selectively target and block the efflux pump in variant antibiotic resistant bacteria."

Antibiotic resistance is becoming a worldwide problem as new forms of resistance can cross countries and continents with ease. Each year in the United States, more than 2 million people acquire serious infections with bacteria that are resistant to one or more of the antibiotics designed to treat those infections, according to the Centers for Disease Control and Prevention. At least 23,000 people die each year as a direct result of these antibiotic resistant infections and many more die from other conditions that were complicated by these infections.

"The development of multi-drug resistant efflux pumps are a major contributor to today's growing epidemic of antibiotic resistance in both Gram-negative and Gram-positive bacteria," comments Dr. Harold Landa, MD., FCCP, a scientific advisor to NanoAntibiotics. "Bacteria use multiple defenses to render antibiotics harmless, including efflux pumps, which transport drugs that actually penetrate the cell back outside of cell walls to protect their nucleus. Utilizing nano-technologies to inhibit efflux pump activity so antibiotics can quickly destroy bacteria has the potential to revitalize the efficacy of many current antibiotics as well as chart a course for new drug discoveries."

Separately, NanoAntibiotics' management would like to provide answers to questions that have been presented as the Company prepared to enter the public domain. The most frequently asked questions are addressed as follows:

Question: Would you please give us a background about NanoAntibiotics?

Answer: NanoAntibiotics was incorporated in April 2013 as a company focused on developing innovative new anti-infective drugs to combat multi-drug resistant bacteria. With our proprietary technology and scientific resources, it was an opportune time to launch the company in the antibiotics sector due to generous federal incentives, changing regulatory framework and growing need to develop alternative therapies to combat antibiotic resistance. It is well known that multi-drug resistant superbugs have become more prevalent and problematic and are becoming a healthcare and financial nightmare here in the USA. Against this backdrop, several large biotech companies are beginning to get back into antibiotics, leaving us in what we believe is an excellent position to advance our compounds and company.

Question: Can you please explain the reason for going public?

Answer: The main reason for going public is to use the capital markets to fund drug development, attract key talent to our company and, lastly, to acquire key technology. I see the success of Cellceutix Corporation, where my father is CEO, and believe that we can achieve rapid growth as well by being a smart and nimble public company. An example of this was their ability to acquire assets from a bankrupt Polymedix, Inc. using cash and stock in bankruptcy court, all accomplished in a short period of time.

Question: Please tell me if you have any affiliation with Cellceutix?

Answer: NanoAntibiotics and Cellceutix are two separate companies that both now happen to be working on antibiotics. NanoAntibiotics was incorporated before Cellceutix had anything to do with Polymedix and antibiotics. I read about the Polymedix bankruptcy and wished at the time that we had the resources to go out and acquire it. Ironically, I guess if NanoAntibiotics would have been established sooner then we ultimately would have been bidding against Cellceutix. I have to give credit to Cellceutix for jumping at the opportunity and successfully acquiring it. Actually, that fits in with our strategy of looking for and acquiring unique technologies that meet our business criteria to grow NanoAntibiotics.

Question: What is NanoAntibiotics' current technology?

Answer: NanoAntibiotics is developing novel nano anti-infective drugs to combat multi-drug resistant bacteria. We are developing a nano efflux pump inhibitor and novel nano antibiotics. I know the first thing that comes to most peoples' mind when using the word "pump" is an actual pump, or some type of extracorporeal medical device. The efflux pump in bacteria is nothing of the sort; it is a matrix of transport proteins involved with removing antibiotics from inside cells. In short, during the pathogenesis of infections, bacteria are able to grow and spread through intrinsic recognition of a drug as foreign and dangerous, triggering a response to "pump" the antibiotic outside its cell walls. The efflux pumps are a key defense mechanism of bacteria that prevents antibiotics from reaching their target and killing it, thus rendering many of today's antibiotics as ineffective. There is quite extensive literature published about this in peer-reviewed medical journals documenting the "learning ability" of bacterium to eliminate drugs from their core. Our Nano Efflux Pump Inhibitor is going after a leading cause of superbug resistance, the ability of bacteria to use their efflux defense.

We are working on making once bacteria-destroying antibiotics effective again. How we are working to do that is by packaging highly purified efflux pump compounds into a nano delivery system, targeting and delivering into the bacteria these large efflux pump inhibitors, effectively stopping the bacteria's drug extrusion ability. These highly purified efflux pump inhibitor compounds that we are researching are proven to not damage mammalian cells. Our goal is to develop a nano efflux pump inhibitor platform that can be easily modified for specific applications for the treatment of bacteria and deadly superbugs.

We have announced successful preliminary laboratory studies on one of our efflux pump inhibitor compounds against certain gram-positive bacteria. Additional studies are ongoing combining our compounds with approved antibiotics against multi-drug resistant bacteria. We look forward to releasing the results of this research in the near future.

Further, we have identified key nano antibiotic compounds from a leading researcher in the field of nanomedicine. We have recently begun studies testing these compounds as well.

Question: Where do you see NanoAntibiotics in the future?

Answer: We already see NanoAntibiotics growing quickly since inception, which we attribute to our innovative compounds and methodology to focus on nano-technology and efflux pump inhibition. We also see an interesting trend where large pharmaceutical companies are licensing compounds that don't necessarily fit their current business model to smaller biotechs, which dovetails with our acquisition and partnering plans. We believe that investors already see the potential as measured by our initial capital raise that was oversubscribed almost immediately. On that point, we feel that we are well positioned to advance our novel compounds from the lab to the clinic and grow into a formidable biotech going forward. There are no FDA approved drugs on the market for efflux pump inhibition, which presents a compelling opportunity. Consider that Mpex Pharmaceuticals partnered with GlaxoSmithKline to develop an efflux pump inhibitor, receiving $8.5 million upfront and a commitment from GSK for commercial milestone payments of up to $250 million for each product candidate in addition to tiered royalties. Our goal is to achieve a similar position in the future.

Bacteria Efflux Pumps:

Bacteria efflux pumps are intrinsic defense mechanisms that expel antibiotics before they reach their target and kill the bacteria. These pumps reside in bacterial cell walls and are a leading cause of multi-drug resistance. There are currently no anti-microbial drugs in use to inhibit the activity of these efflux pumps. There is a need for an effective pump inhibitor which would restore the potency of once effective antibiotics which have been rendered insensitive.

About NanoAntibiotics Inc.

NanoAntibiotics is a developmental stage nano-biotechnology company focused on the development and commercialization of novel therapeutics for multi-drug resistant gram-positive and gram-negative bacteria (also known as Superbugs).

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause NanoAntibiotics' actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. NanoAntibiotics has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are NanoAntibiotics' need for, and the availability of, substantial capital in the future to fund its operations and research and development. The fact that NanoAntibiotics' compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in NanoAntibiotics' filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. NanoAntibiotics undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

INVESTOR AND MEDIA CONTACT:
NanoAntibiotics Inc.
Elliot Ehrlich
(305) 515-4118
Email Contact

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
SYS-CON Events announced today that Dasher Technologies will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Dasher Technologies, Inc. ® is a premier IT solution provider that delivers expert technical resources along with trusted account executives to architect and deliver complete IT solutions and services to help our clients execute their goals, plans and objectives. Since 1999, we'v...
Enterprises have taken advantage of IoT to achieve important revenue and cost advantages. What is less apparent is how incumbent enterprises operating at scale have, following success with IoT, built analytic, operations management and software development capabilities – ranging from autonomous vehicles to manageable robotics installations. They have embraced these capabilities as if they were Silicon Valley startups. As a result, many firms employ new business models that place enormous impor...
We all know that end users experience the Internet primarily with mobile devices. From an app development perspective, we know that successfully responding to the needs of mobile customers depends on rapid DevOps – failing fast, in short, until the right solution evolves in your customers' relationship to your business. Whether you’re decomposing an SOA monolith, or developing a new application cloud natively, it’s not a question of using microservices – not doing so will be a path to eventual b...
SYS-CON Events announced today that Massive Networks, that helps your business operate seamlessly with fast, reliable, and secure internet and network solutions, has been named "Exhibitor" of SYS-CON's 21st International Cloud Expo ®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. As a premier telecommunications provider, Massive Networks is headquartered out of Louisville, Colorado. With years of experience under their belt, their team of...
SYS-CON Events announced today that TidalScale, a leading provider of systems and services, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. TidalScale has been involved in shaping the computing landscape. They've designed, developed and deployed some of the most important and successful systems and services in the history of the computing industry - internet, Ethernet, operating s...
SYS-CON Events announced today that Taica will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Taica manufacturers Alpha-GEL brand silicone components and materials, which maintain outstanding performance over a wide temperature range -40C to +200C. For more information, visit http://www.taica.co.jp/english/.
SYS-CON Events announced today that MIRAI Inc. will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. MIRAI Inc. are IT consultants from the public sector whose mission is to solve social issues by technology and innovation and to create a meaningful future for people.
Transforming cloud-based data into a reportable format can be a very expensive, time-intensive and complex operation. As a SaaS platform with more than 30 million global users, Cornerstone OnDemand’s challenge was to create a scalable solution that would improve the time it took customers to access their user data. Our Real-Time Data Warehouse (RTDW) process vastly reduced data time-to-availability from 24 hours to just 10 minutes. In his session at 21st Cloud Expo, Mark Goldin, Chief Technolo...
SYS-CON Events announced today that IBM has been named “Diamond Sponsor” of SYS-CON's 21st Cloud Expo, which will take place on October 31 through November 2nd 2017 at the Santa Clara Convention Center in Santa Clara, California.
SYS-CON Events announced today that TidalScale will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. TidalScale is the leading provider of Software-Defined Servers that bring flexibility to modern data centers by right-sizing servers on the fly to fit any data set or workload. TidalScale’s award-winning inverse hypervisor technology combines multiple commodity servers (including their ass...
In the fast-paced advances and popularity in cloud technology, one of the most critical factors revolves around concerns for security of your critical data. How to assure both your company and your customers they can confidently trust and utilize your cloud environment is most often top on the list. There is a method to evaluating and providing security that exceeds conventional modes of protecting data both within the cloud as well externally on mobile and other devices. With the public failure...
Join IBM November 1 at 21st Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA, and learn how IBM Watson can bring cognitive services and AI to intelligent, unmanned systems. Cognitive analysis impacts today’s systems with unparalleled ability that were previously available only to manned, back-end operations. Thanks to cloud processing, IBM Watson can bring cognitive services and AI to intelligent, unmanned systems. Imagine a robot vacuum that becomes your personal assistant tha...
In his session at 21st Cloud Expo, Raju Shreewastava, founder of Big Data Trunk, will provide a fun and simple way to introduce Machine Leaning to anyone and everyone. Together we will solve a machine learning problem and find an easy way to be able to do machine learning without even coding. Raju Shreewastava is the founder of Big Data Trunk (www.BigDataTrunk.com), a Big Data Training and consulting firm with offices in the United States. He previously led the data warehouse/business intellige...
Widespread fragmentation is stalling the growth of the IIoT and making it difficult for partners to work together. The number of software platforms, apps, hardware and connectivity standards is creating paralysis among businesses that are afraid of being locked into a solution. EdgeX Foundry is unifying the community around a common IoT edge framework and an ecosystem of interoperable components.
Gemini is Yahoo’s native and search advertising platform. To ensure the quality of a complex distributed system that spans multiple products and components and across various desktop websites and mobile app and web experiences – both Yahoo owned and operated and third-party syndication (supply), with complex interaction with more than a billion users and numerous advertisers globally (demand) – it becomes imperative to automate a set of end-to-end tests 24x7 to detect bugs and regression. In th...